Understanding CAR T-cell therapy persistence in young patients with ALL
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study looks at why CAR T-cell therapy stops working in some children and young adults with leukemia. It aims to help doctors understand how to make this treatment last longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 25 years old or younger.
- You must have a type of leukemia called ALL that has come back or not improved with other treatments.
- You must be scheduled to receive a specific CAR T-cell therapy called tisagenlecleucel, which is approved by the FDA.
- You must give your written consent to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a special immune cell treatment (CAR-T cells) for children whose leukemia or lymphoma has come back or not responded to at least two prior treatments. The goal is to see if these cells can find and destroy the cancer.
This trial tests whether giving two types of CAR T cells (CD19 and CD22) one after the other works better than giving just one type (CD19) followed by a stem cell transplant for people whose B-cell acute lymphoblastic leukemia (B-ALL) has come back or not gone away. The goal is to see which approach offers a better chance of long-term remission.
This early-phase trial tests CAR T-cells made to attack leukemia cells with specific markers (CD19 and CD22). It may help people with difficult-to-treat, relapsed, or high-risk acute lymphoblastic leukemia (ALL), especially when standard treatments haven’t worked well.
This study follows children and young adults who received CAR T-cell therapy for B-cell ALL at least two years ago. It checks long-term side effects, how well the therapy worked over time, and quality of life, so doctors can better understand the lasting impacts of CAR T-cells.
This trial tests a new type of immune therapy called CAR T-cells (engineered to find and attack a protein called CD19 on leukemia cells) for children whose acute lymphoblastic leukemia has come back or hasn't responded to usual treatments. The goal is to see if these special cells can safely help control the disease.
This study follows patients receiving CAR-T cell therapy—an advanced treatment where immune cells are modified to fight leukemia—for acute lymphoblastic leukemia (ALL) that has returned or didn't respond to initial treatment. The trial tracks how well the therapy works and its safety in both children and adults.
Hear when a new Acute Lymphoblastic Leukemia With Failed Remission trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.